Comprehensive analysis of malignant subtypes of lung adenocarcinoma based on multi-omics landscape and functional validation of prognostic biomarker BAIAP2L2.

Lung adenocarcinoma, the predominant pathogenic type of lung cancer, exhibits intricate biological behaviors and molecular pathways, which have consistently been a focal point and challenge in tumor research. The integration of multi-omics technologies and diverse analytical methodologies facilitates an in-depth study of lung adenocarcinoma's characteristics at cellular, molecular, and clinical dimensions, providing a theoretical foundation and prospective targets for precise diagnosis and effective treatment. scRNA-seq and RNA-seq data were obtained from public databases. The epithelial cells of lung adenocarcinoma were analyzed by methods such as CNV level assessment, cell trajectory analysis, malignant cell identification, and cell communication analysis, and the marker genes of malignant cells were extracted. In the RNA-seq data, CoxBoost was used for prognostic modeling to mine the risk gene BAIAP2L2 for further analysis. The effect of BAIAP2L2 on lung adenocarcinoma was verified by cell experiments. There is obvious heterogeneity among the epithelial cells of lung adenocarcinoma, and significant differences exist between different cell subgroups. The malignant differentiation of lung adenocarcinoma cells has a clear trajectory, and epithelial cell subgroups may influence the differentiation direction through cell communication. The CoxBoost model established based on the marker genes of malignant cells has a relatively good predictive effect, and BAIAP2L2 can serve as a prognostic factor for lung adenocarcinoma. In vitro cellular experiments demonstrated that interfering with BAIAP2L2 can impede the proliferation, migration, and invasion of lung adenocarcinoma cells, along with the epithelial-mesenchymal transition of these cells. BAIAP2L2 is a prognostic factor for lung adenocarcinoma, and interfering with BAIAP2L2 can inhibit the growth, metastasis, and epithelial-mesenchymal transition of lung adenocarcinoma.